{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:23:09Z","timestamp":1778275389869,"version":"3.51.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,23]]},"DOI":"10.7759\/cureus.105710","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:06:48Z","timestamp":1774282008000},"source":"Crossref","is-referenced-by-count":1,"title":["Successful Extended Allopurinol Desensitization in an Elderly Patient With Chronic Kidney Disease and Febuxostat Intolerance"],"prefix":"10.7759","author":[{"given":"Rommel","family":"Ramesh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Nagaraja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexei","family":"Gonzalez-Estrada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande KR","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984, 76:47-56. 10.1016\/0002-9343(84)90743-5","journal-title":"Am J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy S","year":"2008","unstructured":"Halevy S, Ghislain PD, Mockenhaupt M, et al.. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008, 58:25-32. 10.1016\/j.jaad.2007.08.036","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp LK","year":"2012","unstructured":"Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, Dalbeth N. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012, 64:2529-36. 10.1002\/art.34488","journal-title":"Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2010.08.002","article-title":"Drug allergy: an updated practice parameter","volume":"105","year":"2010","unstructured":"Drug allergy. an updated practice parameter. Ann Allergy Asthma Immunol. 2010, 105:259-73. 10.1016\/j.anai.2010.08.002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12184","article-title":"Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response","volume":"43","author":"Yun J","year":"2013","unstructured":"Yun J, Mattsson J, Schnyder K, Fontana S, Largiad\u00e8r CR, Pichler WJ, Yerly D. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clin Exp Allergy. 2013, 43:1246-55. 10.1111\/cea.12184","journal-title":"Clin Exp Allergy"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.209","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing","volume":"93","author":"Hershfield MS","year":"2013","unstructured":"Hershfield MS, Callaghan JT, Tassaneeyakul W, Mushiroda T, Thorn CF, Klein TE, Lee MT. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013, 93:153-8. 10.1038\/clpt.2012.209","journal-title":"Clin Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200101)44:1<231::AID-ANR30>3.0.CO;2-7","article-title":"Efficacy and safety of desensitization to allopurinol following cutaneous reactions","volume":"44","author":"Fam AG","year":"2001","unstructured":"Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum. 2001, 44:231-8. 10.1002\/1529-0131(200101)44:1&lt;231::AID-ANR30&gt;3.0.CO;2-7","journal-title":"Arthritis Rheum"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald JD","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, et al.. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020, 72:744-60. 10.1002\/acr.24180","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White WB","year":"2018","unstructured":"White WB, Saag KG, Becker MA, et al.. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018, 378:1200-10. 10.1056\/NEJMoa1710895","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie IS","year":"2020","unstructured":"Mackenzie IS, Ford I, Nuki G, et al.. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020, 396:1745-57. 10.1016\/S0140-6736(20)32234-0","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/476764-successful-extended-allopurinol-desensitization-in-an-elderly-patient-with-chronic-kidney-disease-and-febuxostat-intolerance","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:06:49Z","timestamp":1774282009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/476764-successful-extended-allopurinol-desensitization-in-an-elderly-patient-with-chronic-kidney-disease-and-febuxostat-intolerance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.105710","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,23]]}}}